GFS Advisors LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 36.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,057 shares of the biopharmaceutical company’s stock after selling 32,630 shares during the quarter. GFS Advisors LLC’s holdings in Pfizer were worth $2,470,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its stake in Pfizer by 15.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock valued at $1,967,651,000 after purchasing an additional 7,059,171 shares in the last quarter. Vanguard Group Inc. increased its stake in Pfizer by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock valued at $19,469,816,000 after purchasing an additional 6,620,749 shares in the last quarter. Bessemer Group Inc. increased its stake in Pfizer by 3,845.7% during the 3rd quarter. Bessemer Group Inc. now owns 6,366,640 shares of the biopharmaceutical company’s stock valued at $280,580,000 after purchasing an additional 6,205,282 shares in the last quarter. Macquarie Group Ltd. increased its stake in Pfizer by 20.7% during the 2nd quarter. Macquarie Group Ltd. now owns 25,340,162 shares of the biopharmaceutical company’s stock valued at $919,341,000 after purchasing an additional 4,344,595 shares in the last quarter. Finally, Federated Investors Inc. PA increased its stake in Pfizer by 110.5% during the 2nd quarter. Federated Investors Inc. PA now owns 6,263,587 shares of the biopharmaceutical company’s stock valued at $227,243,000 after purchasing an additional 3,287,377 shares in the last quarter. Hedge funds and other institutional investors own 68.61% of the company’s stock.
In other news, insider Mikael Dolsten sold 149,553 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $43.55, for a total value of $6,513,033.15. Following the sale, the insider now owns 390,097 shares in the company, valued at $16,988,724.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Douglas M. Lankler sold 38,800 shares of the stock in a transaction on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the completion of the sale, the executive vice president now owns 83,592 shares in the company, valued at approximately $3,443,154.48. The disclosure for this sale can be found here. Insiders sold 308,826 shares of company stock worth $13,346,258 in the last quarter. Company insiders own 0.06% of the company’s stock.
PFE has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $53.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Sunday, December 30th. Credit Suisse Group upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating in a research note on Thursday, January 31st. Zacks Investment Research lowered shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Citigroup restated a “neutral” rating and set a $41.00 price target on shares of Pfizer in a research note on Wednesday, February 20th. Finally, UBS Group lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 23rd. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $44.89.
NYSE:PFE opened at $41.78 on Friday. The firm has a market capitalization of $248.71 billion, a PE ratio of 13.93, a price-to-earnings-growth ratio of 2.39 and a beta of 0.76. Pfizer Inc. has a 1-year low of $34.32 and a 1-year high of $46.47. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The firm had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. The business’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.62 earnings per share. Research analysts predict that Pfizer Inc. will post 2.86 EPS for the current fiscal year.
Pfizer announced that its board has authorized a share buyback program on Friday, December 14th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire up to 3.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2019/03/17/pfizer-inc-pfe-position-lowered-by-gfs-advisors-llc.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: Why do commodities matter?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.